CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 20 enrolled
Drug / intervention
Aclidinium Bromide 400 μgdrug
Likely dose
Aclidinium Bromide 400 μgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03276052
NCT03276052Phase 1Completed
CompareCT.gov

A Phase I, Open-Label, Single and Multiple Dose (Twice-Daily), Clinical Trial to Evaluate the Pharmacokinetics, Safety and Tolerability of Aclidinium Bromide 400 μg Administered by Inhalation in Healthy Chinese Participants

AstraZeneca·interventional·Posted Sep 8, 2017·Updated Dec 11, 2023

In Brief

A Phase 1 clinical trial evaluating Aclidinium Bromide 400 μg for Healthy Volunteers. Completed, enrolled 20 participants across 1 site.

Detailed Summary

A Phase I, single centre, open-label study to investigate the pharmacokinetics (PK), safety and tolerability of single and multiple twice daily doses of inhaled Aclidinium Bromide in healthy Chinese male and female subjects.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy Volunteers
CountriesChina
Collaborators--

Timeline

Phase 1CompletedFinished
201820192020202120222023202420252026
First PostedSep 8, 2017
Enrollment StartOct 14, 2021
Primary CompletionNov 26, 2021
TodayJul 2, 2026
Enrollment to primary: 1 monthPosted 8.8 years ago

Interventions

Aclidinium Bromide 400 μgdrug

Aclidinium Bromide 400 μg BID inhalation powder. One oral inhalation via Genuair® dry powder inhaler (DPI)